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1. Introduction
Feline mammary masses are frequently suspected of being mammary tumours. Immediate
attention is required as over 80% of mammary tumours in cats are malignant [1,2], albeit
mammary masses in cats are less common than in dogs. However, prevalence of mammary
tumours is highly variable with the geographic region, as it tends to be lower in areas where
most cats are neutered at a young age. Due to the negative prognosis generally attributed to
feline mammary tumours, little attention has been paid to benign mammary growths and
mastectomy is still often performed to deal with feline mammary fibroepithelial hyperplasia.
Feline mammary fibroepithelial hyperplasia represents a benign, progesterone-associated
fibroglandular proliferation of one or more mammary glands that may occur in both the female
and male cat [3,4]. It is also named feline hypertrophy, fibroadenomatous changes, mammary
hyperplasia or fibroadenoma complex [3-5].
Feline mammary fibroepithelial hyperplasia (FEH) is characterized by the sudden onset of
mammary swollen within a short period of 2 to 5 weeks, frequently concerning several
mammary glands. When exuberant it is often at the origin of the consultation [6-9]. Ulceration
and abscessation of the mammary gland may occur due to gland enlargement and trauma, in
chronic situations [9,10].
Feline mammary fibroepithelial hyperplasia is considered to be a benign condition, yet its
behaviour  and gross  appearance  is  similar  to  mammary  neoplasic  lesions,  in  particular
when solitary ulcerated or violaceous lesions are present. Although it rapid growth may
cause  concern,  fibroepithelial  mammary  lesions  are  reversible,  and  the  volume  of  the
mammary masses tend to decrease after luteolysis or at the end of exogenous progesta‐
gen activity [4,5,11].
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Tentative diagnosis of mammary fibroepithelial hyperplasia should be based on the gross
appearance  of  the  lesions  and  on  the  history  despite  that  most  frequently,  historic
information is  limited or  incomplete,  as  a  previous occurring estrus is  seldom detected.
Thus, diagnosis of feline mammary fibroepithelial hyperplasia is a clinical issue, and is not
difficult  to  be  established  when  all  the  mammary  glands  show  a  rapid  enlargement,
independently  of  the  size  of  the  swollen  mammary  gland [4,9].  This  diagnosis  may  be
further supported by the raised blood progesterone levels or by reported recent proges‐
tin treatment. However, when fibroepithelial lesions develop in only one mammary gland,
distinguish  between hyperplasia  and mammary tumour  may become more  challenging.
Biopsies  or  excision  of  the  mammary  lesions  are  frequently  performed.  Nevertheless,
differential diagnosis with mammary carcinomas has to be carefully established, as around
85% of all mammary neoplasias are malignant [9].
As FEH is a non-neoplastic progesterone-associated disorder, it is possible for most situations
to apply medical treatment. Administration of antiprogestins remains the elective medical
treatment, and its schedule and duration is usually related to the severity of the problem at
presentation. Complete excision of the mammary chain, under the supposition of a mammary
tumour, may become a really aggressive surgery. Nowadays, with the available medical
options mastectomy should be avoided in case of FEH.
Recurrence of the situation, although possible, remains controversial [6,11-13]. Nevertheless
it is an important issue when discussing the therapeutic approach with owners. Ovariohys‐
terectomy remains an option in animals not intent to reproduction and in animals submitted
to progesterone-based contraception, even if postponed until mammary glands regress into
the normal size.
The objective of this work was to present and discuss the clinical approaches available to
establish the diagnosis and the therapeutic options for feline mammary fibroepithelial
hyperplasia. The final purpose in the diagnosis and treatment of such disease is not only to
confirm that the clinical situation was correctly identified, but also to select the most suitable
therapeutic approach to each patient, and also avoiding precipitate mastectomy and other
complications of the surgical act, with the minimum repercussions on patients' welfare.
2. Epidemiology of the feline mammary fibroepithelial hyperplasia
Feline mammary fibroepithelial hyperplasia occurs in intact queens of any age, in pregnant
females and in female or male cats under progestin treatment [6-8,14]. It predominantly affects
younger intact female cats, a segment of the population that also presents an increased ratio
of spontaneous ovulation [15,16]. The reported age range for FEH is 6 months to 13 years
[17-20]. Not so frequently, the condition may also be seen in aged females, associated or not
with a contraceptive treatment, and sporadically in hormonally treated male tomcats. In a local
study, the age range for FEH was 10 months to 10 years (the median for the age was 3 years),
and the condition was exclusively diagnosed in queens [21]. This contrast with the usual age
Insights from Veterinary Medicine216
at presentation in case of mammary neoplasia, which is middle-aged queens, since the risk for
mammary tumour increase with the cat age, particularly at 10-12 years [1,22].
Moreover, few reports exist on the occurrence of FEH in males under treatment with antian‐
drogenic drugs, such as delmadinon acetate (Meisl et al., cited in [8]) and cyproterone acetate
[12], frequently used by cat fanciers for eliminating the urine spraying in intact adult tomcats.
Infrequently, descriptions of FEH in spayed queens or male cats supposedly not submitted to
steroid treatment have been published [11,23], but the doubt remained on the absence of an
involuntary hormonal treatment.
It is generally accepted that the incidence of this disturbance may reach up to 20% of the
mammary masses detected in cats, its prevalence varying with the country or the region,
which reflect  cultural differences in the reproductive management of domestic and free-
roaming felids.  In  a  study developed in  the  north  of  Portugal,  based  on  the  excisional
material sent for histopathology analysis,  the mammary fibroepithelial hyperplasia reach
13%  of  the  feline  mammary  masses  [21].  Nevertheless,  according  to  our  experience,
incidence  of  FEH seems  to  be  in  regression  among the  group of  animals  submitted  to
progesterone-based contraception,  may be  due to  the  fact  that  most  contraceptive  treat‐
ments  are  now  based  in  oral,  veterinary  drugs  (such  as  Megescat®)  instead  of  human
design  depot  products  (like  Depo-Provera®).  Nevertheless,  the  medroxyprogesterone
acetate and the megestrol acetate are the most frequently reported progestin associated to
FEH, in particular when the drug is injected [13,14,18,24].
Mammary enlargement is usually observed within 1-2 weeks after estrus or within 2-6 weeks
after hormone treatment.
Apparently, no breed predisposition has been suggested for FEH. Even so, the majority of the
cases were described in domestic shorthaired cats, which could simply be due to the fact that
it may constitute the majority of the population worldwide.
3. Pathogenesis of the feline mammary fibroepithelial hyperplasia
The exact pathogenesis of FEH remains unclear, although sex steroid involvement has been
acknowledged for long. Progesterone or its synthetic analogues have being recognized as being
at the origin of most of the FEH situations described.
The interaction between the activity of the mammary gland and the sex steroids is recognised
for long. In brief, development and growth of the mammary gland is under the control of
progesterone, which effects are mainly mediated through the progesterone receptor (PR) on
stromal and epithelial cells [25]. Local activation of PR triggers a cascade of specific and
sequential series of molecules, specific for each glandular element, which stimulates mammary
gland proliferation. In physiological conditions, the cyclic changes between estrogens and
progesterone stimulate or repress the cyclic activation of such PR-mediated pathways [25]. A
decrease in PR levels is associated to a reduction of progesterone activity. Progesterone has
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been reported as having a major role in mammary ductal branching [26,27], while estrogens
acting via the ER have been associated to ductal elongation and bifurcation [27].
An aberrant regulation or those pathways may be at the origin of the disturbed response to
the progesterone stimulation and contribute to the development of mammary gland hyper‐
plastic or neoplastic growth. It is possible that such response may be associated to two factors:
the extreme sensitivity of the feline mammary gland to sex steroids action, as referred in older
studies (Bässler, cited in [17]); and the fact that the mammary gland is usually very thin when
non-pregnant or non-lactating [28].
In a recent study, the two progesterone receptors (PR) isoforms (A and B) have been evidenced
in tissue samples from fibroepithelial hyperplasia lesions, with predominant expression in the
ductal epithelium. It was also reported a higher expression of PR in the stroma of FEH lesions
in comparison to those found in stroma from mammary carcinomas [29]. The presence of
estrogen receptors (ER) in FEH lesions remains a subject of controversy, as the number of cases
where ER has been detected varies along the reports [20,30,31]. Nevertheless, a slight reduction
in ER expression seems to accompany the process. Expression of PR in a progesterone-target
tissue is dependant of the previous stimulation by estrogens via ER, while progesterone effects
also include the down-regulation of estrogen receptors. So it is also possible that the length of
progesterone dominance or the circulating levels of progesterone may influence the amount
of ER found in mammary tissue in the available studies.
The potential role of estrogens in the development of fibroepithelial hyperplasia needs
clarification, as it may influence the relationship between the progesterone and estrogen
receptors in mammary gland tissue. Further, in one recent study the concentrations of estradiol
in animals suffering from FEH were higher than values typical for the luteal phase, both in
case of the first appearance of fibroepithelial hyperplasia and in recurrences [13].
Progestagens (progesterone and synthetic progestins) influences on feline mammary glands
result in the stimulation of the cellular proliferation through PR stimulation. It was proposed
that binding of progestagens to PR would enhancement the local GH expression [29,32]. The
GH presents a mitogenic action, which is mediated by insulin-like growth factor-1 (IGF-1)
[32,33], a molecule shown to possess a strong mitogenic and anti-apoptotic effect on the
mammary epithelial cells. The increased expression of GH, GH receptor and IGF-I was
demonstrated in FEH lesions [29].
For fibroadenomatous hyperplasia associated to the cyproterone acetate administration it was
found that this drug may present a “gestagenic” effect, which it was suggested to contribute
to the development of fibroepithelial hyperplasia of mammary glands [12].
Comparative studies of the proliferative index (measured by Ki67/MIB1 expression) in feline
fibroepithelial hyperplasia and other mammary tumours showed that, in spite of being a
benign disturbance, it shows a very high proliferative index similar to the one observed in
invasive mammary carcinomas [34,35]. Fibroepithelial hyperplasia, which exhibits unique
morphological and biological features, is characterised by rapid proliferation of epithelium
and stroma [35]. Regardless its classification as a hyperplastic lesion, with a favourable
biological behaviour, all cases of fibroepithelial hyperplasia exhibited high rates of cell
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proliferation, with mean values similar to those of carcinomas in accordance with the results
of a previous investigation [35].
Despite that increase expression of PR has been found in the FEH lesions in comparison to
normal diestrous mammary tissue samples, the blood levels for progesterone are usually
within the normal levels for the species [6], although cats may present considerable variation
in their progesterone blood levels [36]. This is suggestive that the disease would correspond
to a disturbed, exaggerated response of the tissue to the circulating hormones.
4. Morphological and pathological features of mammary fibroepithelial
hyperplasia lesions
Macroscopically, FEH lesions appear as firm, well-circumscribed but unencapsulated masses,
that may present two types of macroscopic patterns: the solid type, of smooth-surfaced tissue
with scant fluid; and the parenchymal, intraductal pattern, with fluid-filled spaces [18]. The
two patterns can be combined in the same lesion, or one of them can predominate over the
other. The cut surface is solid, diffusely white or grey-white and homogeneous [9,37,38]. Areas
containing gelatinous material may be found, disposed as cleft-like spaces created by the
enlarged ducts [21,37] (Figure 1). Although necrosis or ulceration are rare [17], they can be
found in long lasting situations or whenever the reduction of the mammary gland swelling
was attempted by progestin administration.
Figure 1. Gross appearance of feline mammary fibroepithelial hyperplasia lesions. On the left, the cut surface of a for‐
malin-fixed lesion showing a solid pattern. On the right, the cut surface of a fresh lesion showing several cleft-like
areas (arrow), typical of the intraductal pattern.
Microscopically, the two patterns are similar [18]: the diseased mammary gland is character‐
ized by the proliferation of glandular fibroepithelial elements. The lesions correspond to well-
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demarcated, non-encapsulated growths within the mammary gland [17,31], with the ducts
forming pseudo-acinar or cystic structures, encircled by a loose, myxoid stroma [21]. Although
the proportions of epithelial and connective tissue are variable with the lesion and distinct
from the one found in the normal gland, the branched ducts and stroma retains its organization
in lobular-like units. The branching ductal structures are lined by several layers of epithelial
cells and surrounded by markedly proliferating and oedematous connective tissue. Loose
periductal connective tissue, that gives higher prominence to the mammary stroma, is loose-
textured and merged in the periphery to the more dense collagenous tissue that separates the
mammary lobules [9,17,31,37,38]. Mitotic figures are commonly found both in the epithelium
and the stroma [17,31], and apocrine differentiation is frequently found within the epithelial
component. Further, it is often observed that the cells in the intralobular stroma lack polarity
and show indistinct borders [17], and also some degree of cytological atypia, which is reactive
[21]. Thereby, a falsely malignant appearance is created, which could be patent in the results
for a fine needle aspiration biopsy. An inflammatory infiltrate is seldom found, and when
present it is mostly of the lymphoplasmocitary type [21].
5. Clinical presentation
Usually, the main complaint for FEH is the existence of excessive mammary enlargement that
evolved rapidly. This in fact characterises the disease.
Feline mammary glands thickness is minimal in cycling females, and also it does not change
much until close to parturition [28]. Consequently, for most cases an increase of the volume of
the mammary glands, either isolated or multiple, in otherwise clinically healthy animals,
draws the attention of the cat owner. Time since the beginning of the mammary enlargement
till the animal presentation seems to vary with the form of the FEH. It tends to be shorter in
cases of more notorious swelling of multiple glands and may be longer in cases of solitary and
smaller lesions.
The major clinical sign is the swollen, firm mammary gland tissue, that can be detected in as
multiple, bilateral enlargement of the mammary chains, or develop as a solitary, unique lesion
that may develop from any of the mammary glands (Figure 2). The size of the enlarged glands
is quite variable, ranging from 1.5 to 18 cm [21]. In our experience, when multiple lesions develop,
asymmetrical lesions are more frequently found in non-pregnant females, while females being
pregnant tend to develop more homogeneous swellings of the mammary glands (Figure 2).
At the visual inspection, the skin covering the diseased mammary glands may be tense and
erythematous, in particular in larger lesions. The nipples can be difficult to find due to the size
of the gland. At palpation, the lesions are presented as diffuse, firm and consistent masses, or
in some cases they present a soft and more gelatinous, floating consistency. If notorious
swelling develops, the diseased mammary glands may become pendulous. In uncomplicated
situations and unless the masses are too swollen, the lesions are not painful, although some
distress may be elicit during mammary manipulation during the clinical examination. Further,
when severe swelling of the mammary glands developed, locomotory problems may arise that
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may induce some distress with movement or reluctance to walk and a reduction of appetite.
Less severe lesions usually evolve in the absence of an inflammatory reaction.
Whatever the dimensions of the mammary glands, when FEH develops in pregnant females,
no milk is produced in the diseased glands [23]. Consequently, after parturition, kittens are
unable to nurse satisfactorily and usually the owners refer to litter vocalisation, restless and
fading, with offspring death over a short-time period in postpartum.
In some severe or prolonged situations, the primary FEH may co-exist with mastitis or
ulceration (Figure 2). In our clinic, mastitis is more frequently found in lactating females
suffering from FEH. However, ulceration may develop secondary to perfusion problems
derived from skin overstretching, with local ischemia, leading to abscessation, or also due to
excessive grooming. Ulceration predisposes the diseased gland to mastitis or abscessation and
subsequently to systemic illness [10-12]. In such situations, depending on the severity of the
process, the skin may be wet, exudative, haemorrhagic and abnormal glandular discharge,
with necrotic debris or purulent. Involvement of the regional lymph nodes is possible [10].
Then, the animal may be presented to consultation with fever, lethargy, anorexia, pale mucous
membranes and dehydration.
Little information is available on the haematological and blood biochemistry changes in
animals suffering from FEH. Nevertheless, in animals suffering from non-complicated
mammary fibroepithelial hyperplasia, most parameters analysed (blood haematology and
biochemistry) were within the normal range values for the species [11,14]. In animals with FEH
co-existing with mastitis and ulceration, it can be found anaemia [10,39], normal to increase
packed-cell volume [12,13,39] and the leukocyte count near the maximum normal limit or
increased [10,12,39]. All these changes have been associated to inflammation and/or seques‐
tration of fluid within the distended mammary tissue or to patient dehydration.
On what concerns the blood biochemistry, for most cases the values for blood urea and
creatinine, or for the hepatic enzymes (such as the alkaline phosphatase, the alanine amino‐
transferase and the aspartate aminotransferase) were within the normal limits for cats [11-13],
or slightly decreased [10].
6. Diagnostic evaluation
6.1. Reaching a tentative diagnosis
Diagnosis of feline mammary fibroepithelial hyperplasia is always a clinical issue, and should
be based on the symptoms, the patient signalment and on history [39,40]. Differential diagno‐
ses should include the mammary tumours (adenocarcinoma or carcinoma, mammary adeno‐
ma, or mammary sarcoma) and the mammary fibroepithelial hyperplasia.
Usually it is not difficult to establish a diagnosis when multiple glands are enlarged. An
important criterion is the rapid onset of the mammary swelling, independently of the size of
the swollen mammary gland. Also the age of the female may be suggestive of FEH, as it is
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more frequently found in young females. The sex of the animal should not be an exclusion
criterion, as FEH also develop in males submitted to hormonal treatment for urine spraying
or skin conditions. Neither it should be the reproductive status of the cat, as FEH can develop
in neutered cats with pyoderma or miliary dermatitis following hormonal treatment with
progestins. Moreover, a rapid enlargement of the mammary chains in a early or mid-pregnant
females should lead to the suspicion of FEH, as the mammary glands shows little development
until near parturition in cats. Unless an excessive swelling of the mammary exits, FEH is
painless.
Yet, when fibroepithelial lesions develop in a single mammary gland, distinguishing between
hyperplasia and mammary tumour may become more challenging, particularly in mature or
older animals. As in other FEH conditions, the lesion develops at a very rapid rate, is frequently
painless and although firm it is also turgid with a regular oedematous texture at palpation.
Figure 2. Diverse aspects of feline mammary fibroepithelial hyperplasia. A – A solitary lesion in a female cat submitted
to megestrol acetate treatment. B - Multiple lesions showing asymmetric distribution of the diseased mammary
glands, which also presented different dimensions, in a young spontaneous-ovulatory queen. C – In larger lesions, the
skin around the nipple may be stretched, moist and violet, due to excessive grooming. D – FEH complicated with mas‐
titis and ulceration in a female at post-partum day 6. E – FEH in a peri-partum young female that also showed skin
erosion around the nipples of the caudal mammae.
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Although it should not be considered as a rule, frequently FEH solitary lesions reach larger
volumes than those referred to feline mammary tumours [22], and are softener.
Discoloration of the skin underlying FEH lesions was once reported [41], but I was not able to
confirm that association in my practice.
Occurrence of FEH indicates that the animal ovulated and endogenous progesterone is raised
or that it was treated with progestins. Hence, the mammary fibroepithelial hyperplasia
diagnosis may be further supported by determination of blood progesterone levels. However,
one should be aware that progesterone levels may be low when the underlying cause are
exogenous progestins, because nowadays progesterone analysis are quite specific and may not
cross-label with the used progestin molecule. Thus, it is also of utmost importance to determine
the existence of a recent progestin treatment.
6.2. Diagnostic endorsements
Biopsies are often referred as being the most acceptable form to confirm the diagnosis of
mammary fibroepithelial hyperplasia. However, cytological differentiation between benign
and malignant mammary lesions is difficult. The accuracy of cytological differentiation is low,
and its specificity has not yet been attributable. Further, the cytological analysis should be
interpreted together with the symptoms and the sudden onset of the clinical signs [11].
It should be remembered that mammary fibroepithelial hyperplasia lesions are highly
proliferative [34,35] and that some degree of cytological atypia [21] are often described, which
along with the described loss of cell polarity [17] and the occurrence of mitosis [17,31], can
create a falsely malignant appearance that could biased the diagnosis. Consequently, if a
histopathological diagnosis is wanted, an excisional biopsy is preferable to a fine needle
aspiration, despite being more expensive.
Diagnosis of FEH in cytological specimens should meet the following criteria: Two different
cells (one of uniform epithelial cells and one of spindle-shaped mesenchymal cells) should co-
exist, and may display a moderate anisocytosis and anisokaryosis, with only minimal nuclear
criteria of malignancy. A large amount of eosinophilic extracellular matrix is expectably found
in close proximity to the cells (Mesher, cited in [11]).
Mammary ultrasonography may also be helpful on the diagnosis of feline mammary fibroe‐
pithelial hyperplasia. Furthermore it is a rapid and easily performed method for assessment
of the mammary gland structure. Generally, the ultrasonographic mammary echogenicity is
higher in FEH lesions when compared to normal and lactational feline mammary glands
(Figure 3). On ultrasound images, FEH lesions present mainly as a well-circumscribed solid
mass of granular, slightly hyperechoic texture, with regularly delimited margins. It is also
common to found small cleft-like structures, appearing as irregular anechoic areas, without
acoustic enhancement, and small hyperechoic foci scattered within the glands image, which
are independent of the form of FEH (multiple or solitary form). The presence of clefts in
mammary fibroepithelial lesions provided a more heterogeneous appearance to the ultra‐
sound images. In our practice clefts are more frequently found in animals under progestin
treatment. The ultrasound pattern is more homogeneous in solid lesions, whilst when the
intraductal pattern dominates, anechoic areas corresponding to clefts of different shapes are
found within the mammary gland parenchyma (Figure 4).
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Radiology is of little interest in cases of FEH, as for most situations lateral abdominal surveys
only shows the enlargement of the mammary glands, an intact body wall and sporadically
homogeneous fluid opacity in the diseased mammary glands [10]. In comparison, ultrasonog‐
raphy can bring you more information through the assessment of the lesion echogenicity and
pattern. However, when attempting to establish a differential diagnosis with mammary
carcinoma, thoracic and abdominal radiographs are advised to screen for possible metastases
and calcification.
Figure 3. Ultrasound images of normal feline mammary gland in non-pregnant, late pregnant and lactating females
(from left to right).
Figure 4. Ultrasound images of feline mammary fibroepithelial hyperplasia lesions. On the left, images from a solid pattern
lesion. On the right, images from lesions presenting cleft-like anechoic areas, characteristics of the intraductal pattern.
Finally, confirmation of the tentative diagnosis can also be achieved through the response to
Aglepristone treatment. Aglepristone as an antiprogesterone drug can elicit a positive
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response with a reduction of the mammary swelling and improvement of the clinical condition,
which can be obtained around day 3 post-administration (for the doses and schedule, please
see next section).
7. Therapeutic approaches
In most animals diagnosed with FEH, the extent of the swelling of the mammary glands and
the possibility of necrosis and infection warrant treatment, though this is generally considered
as a benign disturbance [23]. Even so, seldom sporadic recovery is observed [6], and when
described it usually take several weeks to months.
The feline mammary fibroepithelial hyperplasia being a progesterone-associated disturbance,
the therapeutic approach should focus on the removal of the progesterone influences in order
to revert the symptoms. Thus, discontinuing of any ongoing hormone therapy is mandatory.
Available approaches should be discussed with the cat owner, including a prevision of the
costs for the treatment, the time to full recovery and the possibility for the occurrence of a
relapse. For most FEH situations 21-24 days may be needed to fully reversion of the mammary
gland enlargement, but it may vary with the selected therapeutic approach.
In addition to the treatment directed to feline mammary fibroepithelial hyperplasia, situations
complicated with mastitis and skin ulceration or abscessation or systemic illness, additional
treatment targeting the recovery of the inflammatory condition and the stabilization of the
patient may be needed. Adequate broad-spectrum antimicrobial treatment (with Amoxicillin-
Clavulanic acid or Cephradine for example), or fluid replacement may be needed. Also, when
pain or discomfort exists, short-time treatment with nonsteroidal anti-inflammatory drugs
(such as Meloxicam, Ketoprofen or Carprofen) may be used to alleviate the symptoms.
7.1. Surgical approaches
Until the late 90´s decade, ovariectomy or ovariohysterectomy were considered the most
suitable treatments [19]. The lateral surgical approach was preferable to the ventral to avoid
the trauma of the mammary tissue. Excision of the ovaries usually leads to regression of
the mammary tissue within three to four weeks, but in some situations regression was not
achieved [11,23].
Mastectomy is discouraged as a first approach to the feline mammary fibroepithelial hyper‐
plasia. Only in animals not responding to spaying or to the medical treatment, partial or total
mastectomy may be considered, but the surgery is difficult to perform because of the exten‐
siveness of the mammary glands. A radical mastectomy often leads to complications and is
only to be recommended when other options have failed.
7.2. Medical approaches
Nowadays, medical therapeutic approaches are available in most countries. Economic
constraints may influence the drug of choice, and this may influence the recovery time. Also,
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when predicting the recovery time, one should be aware that FEH secondary to exogenous
progestin would take longer to regress if antiprogesterone drugs are not selected.
Several studies demonstrated that the progesterone receptor blocker Aglepristone (Alizine®,
Virbac, France) can successfully revert FEH [8,11,13,19,23]. Aglepristone is a molecule that
competitively binds to the progesterone receptor without activating the hormone response
cascade in target tissues. This drug binds to with a 9-fold affinity to progesterone receptor, and
according to the manufacturer its residence time in the organism is of 6 days, if administered
once in the dose of 20mg/kg or twice at 10mg/kg [23]. Although not licenced to be used in cats,
this drug is commonly used to induce abortion or to treat pyometra in this species. By
consequence, its application in cats is under the veterinarian responsibility.
Before starting the treatment with Aglepristone it is important to exclude pregnancy, as this
drug may elicit abortion of a premature birth. When FEH develops in pregnant females it is
mandatory that the therapeutic approaches are discussed with the cat owner in detail, and is
important to mention that despite the mammary enlargement, the diseased glands will not
produce milk and also that the kittens attempts to nurse may predispose to complications such
as mastitis and ulceration, which will worsen the evolution of the primary condition.
Several therapeutic schedules have been described in the literature for Aglepristone in FEH
(Table 1). Personally, I prefer to inject 10mg/kg of Aglepristone (Alizine®) on days 1 and 3,
subcutaneously (SC), and to re-evaluate the situation a week later. If necessary, a second
administration is performed following the same schedule. Rarely (only one situation in 25 cases
treated with Alisine®) I needed to perform a third administration (again two doses 48h apart),
in a female that was submitted to oral progestin treatment that started during estrus. Reduction
of the mammary volume, in particular the mammary thickness, is the major parameter for
assessment of the response to treatment. Mammary thickness can be assessed by ultrasonog‐
raphy. By using this schedule, it can be observed a slight reduction in the thickness of the
disease mammary glands between days 1 and 3, which is predictive of the expected length of
the treatment. For most cases, FEH recovery was obtained in 3 to 4 weeks, with only one
situation (the one above mentioned) taking 6 weeks to obtain full regression of the mammary
condition.
Varying with the reports, the a mean of 4 to 5 treatments (Table 1) are needed to recover from
FEH [23,42], and full recovery was obtained in varying periods that last for 3 to 11 weeks [23].
Occasionally, short-term skin irritation at the site of injection has been reported [23], but it
seldom originates a problem.
In some case descriptions, dopamine agonists such as Cabergoline and Bromocriptine were
also used for FEH treatment [40]. Though these products were not licenced for cats in some
countries, they are commonly used in the feline practice. Vomiting or anorexia are described
as side effects in a small proportion of cases, as well as a slight depression of the blood pressure,
although these symptoms tend to disappear with continued treatment. Nonetheless, its
usefulness in the treatment of feline mammary fibroepithelial hyperplasia remain uncertain,
as prolactin has not been described as one of the players in FEH pathogenesis and FEH lesions
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are negative to prolactin [43]. Nevertheless, such drugs may be helpful when it is need to
discontinue the queen lactation, in cases where FEH develops in lactating females.
Cabergoline (Galastop®, Ceva Santé Animale, France) is a dopaminergic agonist that produces
a selective and long-lasting inhibitory effect on prolactin secretion, which in turn may be
helpful to supress lactation. In dogs and cats it also induces luteolysis, and consequently it
may induces abortion. Cabergoline is used for interrupt lactation at a dose of 5μg/kg body
weight, per os (PO), once daily for 5-7 consecutive days depending on the severity of the
situation. It is also used for mastitis treatment. Its use was described in association with
castration in a tomcat [11], or in association with aglepristone in an assumed pregnant young
queen [44].
Bromocriptine (Parlodel® is the most frequently used pharmacological presentation) is used
in the veterinary practice less often than Cabergoline, as it was found to induce abnormal
behavioural effects, such as limb flicks, head/body shakes, and hallucinatory-like behaviour
as well as excessive grooming [45]. This drug can be used at the dose of 0.25mg/cat/day, PO,
for 5 to 7 days. Its use on FEH situations enrols the same concerns as for Cabergoline.
8. Prognosis
Generally, the prognosis for uncomplicated feline mammary fibroepithelial hyperplasia is
good. The co-existence of mastitis or ulceration may induce some concern, particularly when
the situation was left untreated for a long period. In rare situations, abscess formation and
systemic illness worsen the prognosis.
Spontaneous regression of the enlarged mammary glands after removal of the progesterone
influences may occur, but it may take up to 11 months. Nevertheless, ovariohysterectomy or
Alizine® doses Treatment schedule References
0,33ml/kg/d corresponding to
10mg/kg/d
2 doses, 24h apart;
Repeat at week intervals to full recovery [13]
4 to 5 consecutive days [19]
4 to 5 consecutive days and again on day 7 [8]
On days 1, 2, 7, 14 and 21 [42]
2 doses, 24h apart, for 4 consecutive weeks
[23]0,66ml/kg/d corresponding to
20mg/kg/d Once a week, for 4 consecutive weeks
0,33ml/kg/d corresponding to
10mg/kg/d On days 1, 2 and 7 [40]0,5ml/kg/d corresponding to
15mg/kg/day
Table 1. Administration regimens proposed for Aglepristone (Alizine®, Virbac, France) treatments in feline mammary
fibroepithelial hyperplasia.
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withdrawal of the progestin treatment does not always result in regression of the masses. With
the available progesterone antagonist, medical treatment of the condition has improved, and
regression of the mammary swelling is usually obtained within a 4-8 weeks interval. It is
possible that the co-existing mammary abscesses may require the surgical drainage of the
abscess content, in a way to hasten the FEH regression [10].
Recurrence of the disease is controversial. Some studies refer that it is rarely observed [11].
However, in the absence of neutering, several reports of FEH in females describe the recurrence
of the condition at a variable timing after the initial treatment [6,23,31]. Consequently,
recurrence of the mammary lesions is important concern particularly in females that can
maintain their full reproductive activity.
Thus, when debating the prognosis with the cat owner, it is important to discuss also the
measures need for avoiding the recurrence of FEH. If a progestin administration for contra‐
ception was the causative agent it should be advised the cat spaying. This should also be
advised whenever the female is not intended for breeding. In cases where the surgery for
neutering is decided it can be performed later, when mammary enlargement regressed,
making the procedure easier for the surgeon and less traumatic for the cat, avoiding undesir‐
able trauma of the enlarged mammary glands during surgery. If progestin was used as
treatment for skin disorders, alternative therapeutics should be found.
9. Concluding remarks
FEH is a progesterone-associated disease that is characterized by a very rapid swelling of
mammary gland, which onset is usually within 2 to 4 weeks from the occurrence of an estrus
or the administration of a progestin treatment. Occasionally, this primary lesion can be
complicated with mastitis, ulceration or abscessation of the diseased mammary glands.
Diagnosis of feline mammary fibroepithelial hyperplasia is exclusively a clinical issue, though
some complementary methods of diagnosis may be helpful aids to confirm the diagnosis.
Treatment of feline mammary fibroepithelial hyperplasia has undergone major changes in the
past three decades, and considerable improvement of cat welfare was achieved with the
introduction of successful medical treatment. Nowadays, antiprogesterone drugs are available
that ease the therapeutics and hastens a favourable outcome. With these drugs, the treatment
targets the major causal mechanism, interrupting the progesterone-mediated pathways of
mammary development and growth. Antiprogesterone molecules are now in the first line
treatments for FEH, allowing to avoid massive mastectomy, a very aggressive approach to the
cat. However, relapses are possible, and most frequently ovariectomy or ovariohysterectomy
are advised to avoid recurrence of the problem.
Nevertheless, new studies on molecular pathways involved in the disease might strengthen
additional interplaying factors of interest to design additional therapeutic approaches, as well
as to highlight the factors underlying the relapses described in the literature in order to
improve the medical treatment and the animal welfare.
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